Health
FDA Approves AbbVie's JUVMO, the First New Type of Dopamine Drug for Parkinson's in Decades
The once-daily pill targets different dopamine receptors than existing options and is expected in U.S. pharmacies this month.
AbbVie News
All Happy News Company coverage of AbbVie: the latest health news, with links to every original source.
Got good news? Let's share it.
Publish your impact story, donation, milestone or community launch on Happy News Company from $99. Nonprofits save 25%.